• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

口服吸附剂对慢性肾衰竭大鼠异常消化道内环境的纠正作用

Correction by oral adsorbent of abnormal digestive tract milieu in rats with chronic renal failure.

作者信息

Okada K, Takahashi S

机构信息

Nishi-Kofu National Hospital, Kofu, Yamanashi, Japan.

出版信息

Nephrol Dial Transplant. 1995;10(5):671-6.

PMID:7566581
Abstract

In order to examine the mechanism by which the oral carbonaceous adsorbent, AST-120 delays the appearance of glomerular sclerosis, experiments were carried out in 120 male Sprague-Dawley rats weighing 285-320 g. The rats were first subjected to 2/3, 3/4, and 4/5 nephrectomy (n = 40). The experiments were begun at 2 weeks after the surgery, and were performed over an 8-week period. Half of each group (n = 20) was administered 1 g/day of liquid AST-120, and the other half received liquid vehicle solution with pair feeding in each group. In the 2/3 nephrectomized group the administration of AST-120 delayed the occurrence of glomerular hypertrophy and prevented the appearance of glomerular sclerosis without any significant differences in renal function, systemic blood pressure (SBP), and urinary protein excretion (U-P). In the 3/4 nephrectomized group the administration of AST-120 delayed the appearance of glomerular hypertrophy and sclerosis with significant decreases in SBP and U-P. In the 4/5 nephrectomized group the administration of AST-120 delayed the appearance of glomerular sclerosis and prevented a decrease in renal function. It is concluded that administration of the oral adsorbent AST-120 delays the occurrence of glomerular sclerosis by delaying the appearance of glomerular hypertrophy, systemic hypertension, and the increase in proteinuria. It can be therefore mentioned that the accumulating substances in the digestive tract worsen the abnormal milieu of chronic renal failure.

摘要

为了研究口服碳质吸附剂AST-120延缓肾小球硬化出现的机制,对120只体重285 - 320克的雄性Sprague-Dawley大鼠进行了实验。首先对大鼠进行2/3、3/4和4/5肾切除术(n = 40)。实验在手术后2周开始,持续8周。每组一半(n = 20)给予1克/天的液体AST-120,另一半给予液体赋形剂溶液并在每组中进行配对喂养。在2/3肾切除组中,AST-120的给药延缓了肾小球肥大的发生并防止了肾小球硬化的出现,而肾功能、全身血压(SBP)和尿蛋白排泄(U-P)没有任何显著差异。在3/4肾切除组中,AST-120的给药延缓了肾小球肥大和硬化的出现,SBP和U-P显著降低。在4/5肾切除组中,AST-120的给药延缓了肾小球硬化的出现并防止了肾功能下降。结论是口服吸附剂AST-120通过延缓肾小球肥大、系统性高血压和蛋白尿增加的出现来延缓肾小球硬化的发生。因此可以提到,消化道中积累的物质会使慢性肾衰竭的异常环境恶化。

相似文献

1
Correction by oral adsorbent of abnormal digestive tract milieu in rats with chronic renal failure.口服吸附剂对慢性肾衰竭大鼠异常消化道内环境的纠正作用
Nephrol Dial Transplant. 1995;10(5):671-6.
2
[Study on the initiation time of drug treatment for chronic renal failure].[慢性肾衰竭药物治疗起始时间的研究]
Nihon Jinzo Gakkai Shi. 1993 Jun;35(6):765-76.
3
Influence of factors in the digestive tract on the progression of chronic renal failure.消化道因素对慢性肾衰竭进展的影响。
Nihon Jinzo Gakkai Shi. 1993 Jan;35(1):1-11.
4
Combination therapy with angiotensin-converting enzyme inhibitor and oral adsorbent of uremic toxins can delay the appearance of glomerular sclerosis and interstitial fibrosis in established renal failure.血管紧张素转换酶抑制剂与尿毒症毒素口服吸附剂联合治疗可延缓已确诊肾衰竭患者肾小球硬化和间质纤维化的出现。
Kidney Blood Press Res. 2004;27(4):218-25. doi: 10.1159/000079869. Epub 2004 Jul 22.
5
Uremic toxins adsorbed by AST-120 promote tubular hypertrophy and interstitial fibrosis in nephrectomized rats.被AST - 120吸附的尿毒症毒素会促进肾切除大鼠的肾小管肥大和间质纤维化。
Kidney Blood Press Res. 2005;28(1):8-13. doi: 10.1159/000080935. Epub 2004 Sep 17.
6
[The effects of oral adsorbent (AST-120) in the experimental model of chronic renal failure--pathophysiological study on renal function, glomerular hypertrophy, mesangial function and glomerular histology].
Nihon Jinzo Gakkai Shi. 1990 Sep;32(9):1001-8.
7
Oral carbonaceous absorbent modifies renal function of renal ablation model without affecting plasma renin-angiotensin system or protein intake.口服含碳吸收剂可改变肾切除模型的肾功能,而不影响血浆肾素 - 血管紧张素系统或蛋白质摄入量。
Clin Exp Nephrol. 2003 Jun;7(2):120-4. doi: 10.1007/s10157-003-0222-6.
8
Carbonic adsorbent AST-120 retards progression of renal failure by additive effect with ACEI and protein restriction diet.碳酸吸附剂AST-120通过与血管紧张素转换酶抑制剂(ACEI)及蛋白质限制饮食产生相加效应来延缓肾衰竭进展。
Clin Exp Nephrol. 2003 Jun;7(2):113-9. doi: 10.1007/s10157-002-0220-0.
9
Effects of oral adsorbent on gene expression profile in uremic rat kidney: cDNA array analysis.口服吸附剂对尿毒症大鼠肾脏基因表达谱的影响:cDNA芯片分析
Am J Kidney Dis. 2003 Mar;41(3 Suppl 1):S8-14. doi: 10.1053/ajkd.2003.50075.
10
[Effect of oral adsorbent AST-120 in rats with chronic renal failure--mechanism of progression of renal failure by dietary protein].
Nihon Jinzo Gakkai Shi. 1992 Mar;34(3):261-71.

引用本文的文献

1
Oral adsorbents for preventing or delaying the progression of chronic kidney disease.用于预防或延缓慢性肾脏病进展的口服吸附剂。
Cochrane Database Syst Rev. 2014 Oct 15;2014(10):CD007861. doi: 10.1002/14651858.CD007861.pub2.